Chronic kidney disease and peptides — the FLOW trial, the SGLT2-inhibitor backbone, and the peptide signals that sit on top of them

Why this dossier exists

Chronic kidney disease is the indication in which the GLP-1 receptor agonist class produced the most consequential positive peptide-class clinical-trial readout of the 2020s, and where the standard of care simultaneously underwent its largest reorganisation since the introduction of renin-angiotensin-system blockade three decades earlier. The small-molecule SGLT2 inhibitor class — dapagliflozin in Heerspink et al. 2020 DAPA-CKD and empagliflozin in The EMPA-KIDNEY Collaborative Group, NEJM 2023, 388:117–127 (EMPA-KIDNEY) — produced 39% and 28% reductions in primary kidney composite outcomes across 4,304 and 6,609 patients. The non-steroidal mineralocorticoid antagonist finerenone added a third pillar via Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G, NEJM 2020, 383:2219–2229 (FIDELIO-DKD) — an 18% reduction in the primary kidney composite across 5,734 T2D-CKD patients on maximally-tolerated RAS blockade. In May 2024 the peptide entered the same indication: the FLOW trial in Perkovic et al. 2024 reported that once-weekly semaglutide 1 mg reduced major kidney disease events by 24% (HR 0.76; 95% CI 0.66–0.88; P=0.0003) and all-cause mortality by 20% (HR 0.80; 95% CI 0.67–0.95; P=0.01) across 3,533 patients with T2D and CKD. The peptide arrival did not replace the SGLT2-inhibitor pillar; it stacked on top of it.

This dossier walks the peptide and peptide-adjacent evidence base for CKD, separates trial-supported signals from mechanism extrapolation, and frames the picture against the non-peptide backbone that defines modern CKD pharmacology. The honest read across the corpus: the FLOW result is the most clinically rigorous positive peptide-class kidney trial ever conducted, semaglutide is now a guideline-level addition to the CKD-in-T2D pharmacology stack, and almost every other peptide on this list sits in either secondary-analysis signal or mechanism-extrapolation territory.